Kaplan Matthew L.
SEC CIK 1895952 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NVCT | Nuvectis Pharma, Inc. | Dir | 159.8K | $114.9K | — | 6 | 2022-05-12 | 2026-06-11 |
Most active insiders at NVCT, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Mosseri Marlio Charles | 10% | $1.87M | — |
| 2 | BENTSUR RON | COB, CEO, Dir, 10% | $278.6K | — |
| 3 | Sanchez Juan | Dir | $75.3K | — |
| 4 | Kaplan Matthew L. | Dir | $64.2K | — |
| 5 | Poradosu Enrique | Chief Science, Business Off | — | — |
| 6 | Carson Michael J. | VP, Fin | — | — |
| 7 | Shemesh Shay | Chief Dev, Ops. Off | — | — |
| 8 | Hoberman Kenneth | Dir | — | — |
| 9 | Oliviero James F III | Dir | — | — |
Transactions 6
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-12 16:10 | 2026-06-11 | NVCT | Nuvectis Pharma, Inc. | Kaplan Matthew L. | Dir | A - Grant | $0.00 | +35.0K | 159.8K | +28% | $0 | |
| 2025-11-06 | 2025-11-05 | NVCT | Nuvectis Pharma, Inc. | Kaplan Matthew L. | Dir | P - Purchase | $5.84 | +11.0K | 124.8K | +10% | +$64.2K | |
| 2025-06-12 | 2025-06-12 | NVCT | Nuvectis Pharma, Inc. | Kaplan Matthew L. | Dir | A - Grant | $0.00 | +30.0K | 113.8K | +36% | $0 | |
| 2024-06-13 | 2024-06-13 | NVCT | Nuvectis Pharma, Inc. | Kaplan Matthew L. | Dir | A - Grant | $0.00 | +30.0K | 83.8K | +56% | $0 | |
| 2023-06-20 | 2023-06-16 | NVCT | Nuvectis Pharma, Inc. | Kaplan Matthew L. | Dir | A - Grant | $0.00 | +18.0K | 53.8K | +50% | $0 | |
| M | 2022-05-16 | 2022-05-12 | NVCT | Nuvectis Pharma, Inc. | Kaplan Matthew L. | Dir | P - Purchase | $16.88 | +3,000 | 35.8K | +9% | +$50.6K |
Purchase Sale Sale after option exercise All abbreviations